Veterinary Medicine Commons^™

Equine Disease Model For Herpesvirus Neurologic Disease And Uses Thereof, George P. Allen, Glenda Ross

Veterinary Science Faculty Patents

Disclosed is an in vivo equine disease model and a method of preparing the disease model for equine herpesvirus-1 neurological disease comprising a horse having a low preexposure level of herpesvirus-specific CTL precursors wherein the horse is experimentally infected with a neuropathogenic strain of equine herpesvirus or a mutant thereof. Also disclosed is a method of quantifying the risk factors and predicting the development of clinical neurologic signs of equine herpesvirus-1 neurological disease in a horse. Also described in the invention is the determination of the risk of developing the clinical neurologic signs by a mathematical equation. A new live, …

Diagnosis Of Strongylus Vulgaris, Martin K. Nielsen, Ulla Anderson, Daniel K. Howe

Veterinary Science Faculty Patents

Embodiments of the presently-disclosed subject matter provide an isolated polypeptide comprising the sequence of SEQ ID NO: 1, fragments thereof, and/or epitopes thereof. Embodiments of the presently-disclosed subject matter also provide methods for diagnosing a Strongylus vulgaris infection in a subject that comprises providing a biological sample from the subject and contacting the sample with the present isolated polypeptide, fragment thereof, and/or epitope thereof. In some embodiments theStrongylus vulgaris infection can be detected during a prepatent period. In further embodiments the subject is a horse.

Genetically Engineered Equine Influenza Virus And Uses Thereof, Peter Palese, Adolfo Garcia-Sastre, Thomas Chambers

Veterinary Science Faculty Patents

The present invention relates, in general, to attenuated equine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated equine influenza viruses having modifications to an equine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.

Method For Screening For A Tobiano Coat Color Genotype, Ernest Bailey, Samantha A. Brooks

Veterinary Science Faculty Patents

A method for screening for a Tobiano genotype includes obtaining a nucleic acid from an equine animal, and analyzing the nucleic acid for the presence of an inversion in a chromosome ECA3q which is indicative of the genotype for Tobiano. The method includes detecting at least one of a telomeric breakpoint of an inverted ECA3q chromosome and/or a centromeric breakpoint of an inverted ECA3q chromosome. In one embodiment, the nucleic acid may be analyzed by the steps of hybridizing the group of probes or primers having the sequences set forth herein in SEQ ID NO:8, SEQ ID NO: 9, and …

Infectious Cdna Clone Of The Modified Live Virus Vaccine Strain Of Equine Arteritis Virus, Udeni B. R. Balasuriya, Peter J. Timoney, Jianquan Wang

Veterinary Science Faculty Patents

An isolated polynucleotide molecule includes a DNA sequence encoding an infectious RNA molecule encoding a modified live viral strain of an Equine arteritis virus, wherein the DNA sequence is SEQ ID NO:1 or a degenerate variant thereof. Also provided are transformed or transfected host cells including that sequence, vectors including the sequence, and isolated infectious RNA molecules encoded by the sequence. Further, a modified DNA sequence encoding an infectious RNA molecule encoding a modified live viral strain of an Equine arteritis virus is provided wherein the DNA sequence is SEQ ID NO:2 or a degenerate variant thereof, including a silent …

Nucleic Acids Encoding Sarcocystis Neurona Antigen And Uses Thereof, Daniel K. Howe

Veterinary Science Faculty Patents

The present invention provides novel isolated nucleic acids encoding antigenic proteins derived fromSarcocystis neurona, or unique fragments thereof. In particular, the invention provides novel isolated nucleic acids encoding membrane-associated polypeptides SnSAG2, SnSAG3, and SnSAG 4. Also provided are purified antigenic polypeptide fragments encoded by the novel nucleic acid sequences set forth herein that encode for SnSAG2, SnSAG3, and SnSAG 4. Also provided are isolated nucleic acids capable of selectively hybridizing with the nucleic acid from Sarcocystis neurona. The invention also provides vectors comprising the nucleic acids of the invention encoding an antigenic protein derived from Sarcocystis neurona or a …

Nucleic Acids Encoding Sarcocystis Neurona Antigen And Uses Thereof, Daniel K. Howe

Veterinary Science Faculty Patents

The present invention provides novel isolated nucleic acids encoding antigenic proteins derived from Sarcocystis neurona, or unique fragments thereof. In particular, the invention provides novel isolated nucleic acids encoding membrane-associated polypeptides SnSAG2, SnSAG3, and SnSAG4. Also provided are purified antigenic polypeptide fragments encoded by the novel nucleic acid sequences set forth herein that encode for SnSAG2, SnSAG3, and SnSAG4. Also provided are isolated nucleic acids capable of selectively hybridizing with the nucleic acid from Sarcocystis neurona. The invention also provides vectors comprising the nucleic acids of the invention encoding an antigenic protein derived from Sarcocystis neurona or a …

Long Acting, Reversible Veterinary Sedative And Analgesic And Method Of Use, Thomas Tobin

Veterinary Science Faculty Patents

A veterinary composition comprising a guanidine derivative, e.g., guanabenz or guanabenz acetate is provided which produces a rapid acting and long lasting sedative and analgesic effect in a subject animal that is selectively reversible. The use of guanabenz in the horse provides for a safe, effective, long lasting and rapidly reversible sedative and analgesic which can be used on the standing animal. Methods of use of the compositions of the invention are also provided.

Nucleic Acids Encoding Sarcocystis Neurona Antigen And Uses Thereof, Daniel K. Howe

Veterinary Science Faculty Patents

The present invention provides novel isolated nucleic acids encoding antigenic proteins derived from Sarcocystis neurona, or unique fragments thereof. In particular, the invention provides novel isolated nucleic acids encoding membrane-associated polypeptides SnSAG2, SnSAG3, and SnSAG4. Also provided are purified antigenic polypeptide fragments encoded by the novel nucleic acid sequences set forth herein that encode for SnSAG2, SnSAG3, and SnSAG4. Also provided are isolated nucleic acids capable of selectively hybridizing with the nucleic acid from Sarcocystis neurona. The invention also provides vectors comprising the nucleic acids of the invention encoding an antigenic protein derived from Sarcocystis neurona or …

Compounds Encoding The Protective M-Like Protein Of Streptococcus Equi And Assays Therefor, John F. Timoney, Sergey Artiushin

Veterinary Science Faculty Patents

The present invention relates generally to molecular compounds which encode the protective M-like protein of Streptococcus equi (SeM), the amino acid compound which is thereby encoded, and compositions of matter which incorporate either the encoding compounds or the cellular components for which they encode. For instance, vaccines which utilize the amino acid compounds or vectors and cell lines useful to make the amino acid compounds described herein are subjects of the present invention. The present invention provides methods to stimulate S. equi-specific immune response in horses. It also provides diagnostic assays for Streptococcus equi.

Sarcocystis Neurona Diagnostic Primer And Its Use In Methods Of Equine Protozoal Myeloencephalitis Diagnosis, Clara K. Fenger, David E. Granstrom, Alvin A. Gajadhar, Jitender P. Dubey

Veterinary Science Faculty Patents

An amplification primer and probe which can be used in an in vitro diagnostic test for the presence of S. neurona in equine blood or cerebrospinal fluid. Sarcocystis neurona is responsible for the equine condition of protozoal myelitis. The amplification primer is seventeen nucleotides in length and complementary to a unique section of the small ribosomal subunit of Sarcocystis neurona. The primer encompasses nucleotide positions 1470-1487 of the small ribosomal subunit of S. neurona. The primer has the sequence 5' CCATTCCGGACGCGGGT SEQ ID NO:1.

Formulations And Methods To Treat And Prevent Equine Protozoal Myeloencephalitis, David E. Granstrom, Thomas Tobin

Veterinary Science Faculty Patents

The present invention provides formulations useful to treat EPM. It also provides methods to treat EPM in a horse in need of such treatment, comprising administering a pharmaceutically effective amount of a triazine-based anti-coccidial. Preferred are methods to treat EPM using clazuril, diclazuril, toltrazuril or letrazuril. The present invention also provides methods to prevent S. neurona infection in horses comprising administering a prophylactic amount of a triazine-based anticoccidial. Preferred is a method to prevent S. neurona infection by using clazuril, diclazuril, toltrazuril or letrazuril, alone or in combination with other known therapeutics.

Qualitative Metabolism Assessment Using High Performance Thin Layer Chromatography, Shih-Ling Chang

Veterinary Science Faculty Patents

A method for the qualitative assessment of oxidative drug metabolism deficiencies, preferably for the qualitative assessment of dextromethorphan metabolism, in a subject comprises analyzing a sample fluid from the subject, for example urine, which contains metabolites of a probe drug using high performance thin layer chromatography.

Composition For Topical And Infusion Treatment Of Wounds And Burns, Thomas W. Swerczek

Veterinary Science Faculty Patents

A composition is provided for the treatment of contagious equine metritis, a contagious venereal disease of horses. The composition appears to function as a biological inhibitor and has antibacterial and antifungal activity when applied to the normal flora and secretions of the epidermis and mucous membranes. Also, the composition has antipruritic and anti-inflammatory activity. The composition is efficacious in the treatment of lesions produced by bacteria, fungi, allergies, viruses, trauma, and burns to the epidermis, dermis, muscles and mucous membranes of the surface or in body cavities of animals and man.

The composition preferably comprises an aqueous solution of dextrose, …

Treatment For Contagious Equine Metritis, Thomas W. Swerczek

Veterinary Science Faculty Patents

A composition is provided for the treatment of contagious equine metritis, a contagious veneral disease of horses, which composition comprises an aqueous solution of dextrose, a buffering mixture to provide a pH of about 3.0 to 4.5, and a carrier, the composition being applied topically to external genitalia of horses.

Detection Of Morphine And Its Analogues Using Enzymatic Hydrolysis, Joan Combie, Jerry W. Blake, Thomas E. Nugent, Thomas Tobin

Veterinary Science Faculty Patents

The invention relates to a method for hydrolyzing drug glucuronic acid conjugates present in mammalian body fluids, the conjugates being derived from a narcotic analgesic, antagonist, or agonist-antagonist whose metabolism includes conjugation with glucuronic acid. The method comprises incubating the body fluid sample at from about 60 to about 70° C., for at least about 1 hour, with 3-glucuronidase derived from Patella vulgata, and substantially increases the sensitivity of chromatographic techniques for the detection of morphine and its analogues.

Inactivated Equine Rhinopneumonitis Virus Vaccine And Use Thereof, John T. Bryans

Veterinary Science Faculty Patents

An inactivated viral vaccine for protecting horses against disease caused by equine rhinopneumonitis virus is prepared by propagating an equine rhinopneumonitis virus in a susceptible, cloned, diploid equine cell line, harvesting the resulting virus in a serum-free medium, inactivating the virus and neutralizing the inactivating agent, concentrating the virus, and adding an immunological adjuvant thereto. A vaccination program to protect horses against the equine rhinopneumonitis virus is also disclosed.

Process Of Producing Equine Viral Arteritis Vaccine And Product Thereof, John T. Bryans, William H. Mccollum, James C. Wilson, Elvis R. Doll

Veterinary Science Faculty Patents

A process is disclosed for producing an avirulent attenuated live virus vaccine for use in immunizing horses against equine viral arteritis and for simultaneously obviating the transmission of the disease from a vaccinated horse to a non-vaccinated horse. The invention also includes the product derived from practice of the process and typical examples of the efficacy of the product are disclosed.